BBT-031
Growth hormone deficiency
PreclinicalActive
Key Facts
About Bolder Biotechnology
Bolder Biotechnology is a private, preclinical-stage biotech firm leveraging its protein engineering platform to design next-generation cytokine therapeutics. The company's approach centers on creating modified proteins with extended half-lives and enhanced activity profiles, targeting significant markets in oncology, autoimmune disorders, and hematology. As a long-standing entity founded in 2001, it has sustained research and development efforts, though it operates as a pre-revenue company reliant on private investment and partnerships. Its success hinges on advancing its lead candidates into clinical trials and securing strategic collaborations to fund development.
View full company profileTherapeutic Areas
Other Growth hormone deficiency Drugs
| Drug | Company | Phase |
|---|---|---|
| Human Growth Hormone Biosimilar | USV Biologics Division | Phase 2 |
| MOD‑4023 (hGH‑CTP) | Opko Biologis | Phase 3 |
| Inpegsomatropin Injection (Pegpesen®) | Amoytop Biotech | Approved |